Innoviva (INVA) EBIAT (2010 - 2026)
Innoviva posted quarterly EBIAT of $186.6 million for Q1 2026, up 500.56% year-on-year from $31.1 million in Q1 2025, and up 250.12% on a QoQ basis from -$124.3 million in Q4 2025.
Innoviva (INVA) has 17 years of EBIAT data on file, last reported at $186.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBIAT rose 500.56% year-over-year to $186.6 million; the trailing twelve-month figure through Mar 2026 stood at $215.9 million (up 378.73% YoY), and the FY2025 full-year result was $271.2 million, up 1059.22% from the prior year.
- EBIAT for Q1 2026 stood at $186.6 million, up from -$124.3 million in the prior quarter.
- Across five years, EBIAT topped out at $229.3 million in Q3 2022 and bottomed at -$124.3 million in Q4 2025.
- The 5-year median for EBIAT is $21.4 million (2022), against an average of $32.4 million.
- Peak annual rise in EBIAT reached 7312.04% in 2025, while the deepest fall reached 4880.69% in 2025.
- A 5-year view of EBIAT shows it stood at -$10.3 million in 2022, then slumped by 92.43% to -$19.8 million in 2023, then surged by 113.1% to $2.6 million in 2024, then tumbled by 4880.69% to -$124.3 million in 2025, then soared by 250.12% to $186.6 million in 2026.
- The last three EBIAT figures came in at $186.6 million (Q1 2026), -$124.3 million (Q4 2025), and $89.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 186.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.60 Mn |
| Dec 31, 2025 | -124.30 Mn |
| Sep 30, 2025 | 89.91 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.58 Mn |
| Dec 31, 2024 | 2.60 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -34.69 Mn |
| Mar 31, 2024 | 36.53 Mn |
| Dec 31, 2023 | -19.85 Mn |
| Sep 30, 2023 | 82.05 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 34.87 Mn |
| Dec 31, 2022 | -10.31 Mn |
| Sep 30, 2022 | 229.35 Mn |
| Jun 30, 2022 | 21.37 Mn |
| Mar 31, 2022 | 37.86 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 102.65 Mn |
| Jun 30, 2021 | 110.85 Mn |
| Mar 31, 2021 | 109.70 Mn |
| Dec 31, 2020 | -6.62 Mn |
| Sep 30, 2020 | 41.62 Mn |
| Jun 30, 2020 | 98.23 Mn |
| Mar 31, 2020 | 78.95 Mn |
| Dec 31, 2019 | 57.86 Mn |
| Sep 30, 2019 | 47.05 Mn |
| Jun 30, 2019 | 46.06 Mn |
| Mar 31, 2019 | 40.02 Mn |
| Dec 31, 2018 | 269.22 Mn |
| Sep 30, 2018 | 50.17 Mn |
| Jun 30, 2018 | 56.62 Mn |
| Mar 31, 2018 | 30.33 Mn |
| Dec 31, 2017 | 58.51 Mn |
| Sep 30, 2017 | 23.77 Mn |
| Jun 30, 2017 | 35.15 Mn |
| Mar 31, 2017 | 16.85 Mn |
| Dec 31, 2016 | 25.47 Mn |
| Sep 30, 2016 | 15.03 Mn |
| Jun 30, 2016 | 14.60 Mn |
| Mar 31, 2016 | 4.44 Mn |
| Dec 31, 2015 | 4.30 Mn |
| Sep 30, 2015 | -4.58 Mn |
| Jun 30, 2015 | -7.81 Mn |
| Mar 31, 2015 | -10.67 Mn |
| Dec 31, 2014 | -15.93 Mn |
| Sep 30, 2014 | -21.27 Mn |
| Jun 30, 2014 | -20.15 Mn |
| Mar 31, 2014 | -16.18 Mn |
| Dec 31, 2013 | -8.89 Mn |
| Sep 30, 2013 | -9.45 Mn |
| Jun 30, 2013 | -1.54 Mn |
| Mar 31, 2013 | -10.75 Mn |
| Dec 31, 2012 | -43.47 Mn |
| Sep 30, 2012 | -34.69 Mn |
| Jun 30, 2012 | -37.12 Mn |
| Mar 31, 2012 | 84.59 Mn |
| Dec 31, 2011 | -37.01 Mn |
| Sep 30, 2011 | -30.63 Mn |
| Jun 30, 2011 | -25.05 Mn |
| Mar 31, 2011 | -22.67 Mn |
| Dec 31, 2010 | -19.44 Mn |
| Sep 30, 2010 | -21.22 Mn |
| Jun 30, 2010 | -20.81 Mn |